John L. LaMattina's most recent trade in PureTech Health Plc - ADR was a trade of 59,202 Ords 0.01p done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PureTech Health Plc - ADR | John L. LaMattina | Non-Executive Director | 01 Jul 2025 | 59,202 | 1,543,494 (0%) | 0% | 0 | Ords 0.01p | ||
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 30,724 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.30 per share. | 27 Nov 2024 | 2,406 | 31,921 (0%) | 0% | 52.3 | 125,834 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 2,406 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 123.65 per share. | 27 Nov 2024 | 2,406 | 29,515 (0%) | 0% | 123.7 | 297,502 | Common Stock |
| PureTech Health Plc - ADR | John L. LaMattina | Non-Executive Director | 29 Oct 2024 | 52,640 | 1,484,292 (0%) | 0% | 0 | Ords 0.01p | ||
| PureTech Health Plc - ADR | John L. LaMattina | Non-Executive Director | 26 Jun 2024 | 17,122 | 1,431,652 (0%) | 0% | 0 | Ords 0.01p | ||
| PureTech Health Plc - ADR | John L. LaMattina | Non-Executive Director | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 24 Jun 2024 | 54,882 | 1,359,648 (0%) | 0% | 2.5 | 137,205 | Ords 0.01p |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 29,515 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 28,263 (0%) | 0% | 0 | Common Stock | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 4.00 per share. | 15 Jan 2023 | 15,125 | 66,953 | - | 4 | 60,500 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 4,484 | 4,484 | - | - | Non-Qualified Stock Option (right to buy) | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 26,402 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 161.86 per share. | 16 Nov 2021 | 4,835 | 25,398 (0%) | 0% | 161.9 | 782,579 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.30 per share. | 16 Nov 2021 | 4,835 | 30,233 (0%) | 0% | 32.3 | 156,171 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 4,835 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 25,398 (0%) | 0% | 0 | Common Stock | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 3,750 | 3,750 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | John L. LaMattina | Director | Purchase of securities on an exchange or from another person at price $ 18.58 per share. | 24 May 2021 | 5,102 | 51,828 | - | 18.6 | 94,795 | Common Stock |
| Immunome Inc | John L. LaMattina | Director | Purchase of securities on an exchange or from another person at price $ 18.44 per share. | 24 May 2021 | 338 | 46,726 | - | 18.4 | 6,233 | Common Stock |
| Immunome Inc | John L. Lamattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2020 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | John L. Lamattina | Director | 06 Oct 2020 | 46,388 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Immunome Inc | John L. Lamattina | Director | 06 Oct 2020 | 46,388 | 46,388 | - | - | Common Stock | ||
| Immunome Inc | John L. Lamattina | Director | 06 Oct 2020 | 11,111 | 11,111 | - | - | Warrant (right to buy) | ||
| Immunome Inc | John L. Lamattina | Director | 06 Oct 2020 | 11,111 | 0 | - | - | Warrant (right to buy) |